CO4480020A1 - Formulaciones farmaceuticas - Google Patents

Formulaciones farmaceuticas

Info

Publication number
CO4480020A1
CO4480020A1 CO96061449A CO96061449A CO4480020A1 CO 4480020 A1 CO4480020 A1 CO 4480020A1 CO 96061449 A CO96061449 A CO 96061449A CO 96061449 A CO96061449 A CO 96061449A CO 4480020 A1 CO4480020 A1 CO 4480020A1
Authority
CO
Colombia
Prior art keywords
formulation according
active drug
molecular weight
aqueous media
active
Prior art date
Application number
CO96061449A
Other languages
English (en)
Spanish (es)
Inventor
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of CO4480020A1 publication Critical patent/CO4480020A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO96061449A 1995-11-21 1996-11-21 Formulaciones farmaceuticas CO4480020A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
CO4480020A1 true CO4480020A1 (es) 1997-07-09

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96061449A CO4480020A1 (es) 1995-11-21 1996-11-21 Formulaciones farmaceuticas

Country Status (29)

Country Link
EP (1) EP0862437A1 (cs)
JP (1) JPH10513481A (cs)
KR (1) KR19990071505A (cs)
CN (1) CN1215993A (cs)
AP (1) AP718A (cs)
AR (1) AR004335A1 (cs)
AU (1) AU709560B2 (cs)
BG (1) BG102438A (cs)
BR (1) BR9611626A (cs)
CA (1) CA2232715A1 (cs)
CO (1) CO4480020A1 (cs)
CZ (1) CZ155498A3 (cs)
GB (1) GB9523752D0 (cs)
HR (1) HRP960554A2 (cs)
HU (1) HUP9903734A3 (cs)
IS (1) IS4706A (cs)
MA (1) MA26410A1 (cs)
MX (1) MX9804008A (cs)
NO (1) NO982302L (cs)
NZ (1) NZ322053A (cs)
OA (1) OA10687A (cs)
PE (1) PE22898A1 (cs)
PL (1) PL326981A1 (cs)
SK (1) SK63098A3 (cs)
TN (1) TNSN96141A1 (cs)
TR (1) TR199800902T2 (cs)
WO (1) WO1997018814A1 (cs)
YU (1) YU62096A (cs)
ZA (1) ZA969722B (cs)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
WO1999030697A2 (en) * 1997-12-16 1999-06-24 Pfizer Products Inc. Combination effective for the treatment of impotence
WO1999047128A1 (en) 1998-03-19 1999-09-23 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Oral matrix formulations of doxazosin
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) * 2004-11-20 2007-02-07 대우약품공업주식회사 독사조신을 포함하는 서방성 정제
KR20080037732A (ko) * 2005-08-22 2008-04-30 노파르티스 아게 ｐＨ-의존성 약물, ｐＨ 개질제 및 지연제를 포함하는제약학적 조성물
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
WO2007127630A1 (en) 2006-04-26 2007-11-08 Supernus Pharmaceuticals, Inc Controlled released preparations of oxcarbazepine having sigmoidal release profile
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EP2016079A1 (de) 2006-05-04 2009-01-21 Boehringer Ingelheim International GmbH Polymorphe
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN100396282C (zh) * 2006-07-25 2008-06-25 山东省医药工业研究所 甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
MX2010009990A (es) 2008-03-11 2010-12-15 Depomed Inc Formas de dosificación gástricas retentivas de liberación prolongada que comprenden combinaciones de un analgésico no opioide y un analgésico opioide.
PE20091730A1 (es) 2008-04-03 2009-12-10 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20200118243A (ko) 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
DK2395983T3 (da) 2009-02-13 2020-07-13 Boehringer Ingelheim Int Farmaceutisk sammensætning omfattende en sglt2-inhibitor, en dpp-iv-inhibitor og eventuelt et yderligere antidiabetisk middel og anvendelser deraf
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
WO2010123930A2 (en) 2009-04-20 2010-10-28 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
NZ599298A (en) 2009-11-27 2014-11-28 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
MX366325B (es) 2010-05-05 2019-07-05 Boehringer Ingelheim Int Terapia de combinacion.
AU2011276254B2 (en) 2010-07-09 2016-11-03 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
WO2012054523A2 (en) 2010-10-19 2012-04-26 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX2013007884A (es) 2011-01-07 2013-09-13 Elcelyx Therapeutics Inc Terapias a base de ligando del receptor quimiosensorial.
CN102058555A (zh) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 一种多沙唑嗪控释片
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CN102188431A (zh) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 甲磺酸多沙唑嗪缓释片及其制备方法
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3003297A4 (en) 2013-06-05 2017-04-19 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
CN105616378A (zh) * 2014-10-31 2016-06-01 康普药业股份有限公司 一种氟康唑胶囊及其制备方法
CA3022202A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (it) * 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
AU652952B2 (en) * 1990-07-23 1994-09-15 Alza Corporation Oral osmotic device for delivering nicotine

Also Published As

Publication number Publication date
PL326981A1 (en) 1998-11-09
PE22898A1 (es) 1998-05-07
MX9804008A (es) 1998-09-30
ZA969722B (en) 1998-05-20
TR199800902T2 (xx) 1998-09-21
MA26410A1 (fr) 2004-12-20
EP0862437A1 (en) 1998-09-09
AP718A (en) 1999-01-06
NO982302L (no) 1998-07-17
HRP960554A2 (en) 1998-02-28
WO1997018814A1 (en) 1997-05-29
OA10687A (en) 2002-11-27
TNSN96141A1 (fr) 2005-03-15
AU7572196A (en) 1997-06-11
BR9611626A (pt) 1999-06-01
KR19990071505A (ko) 1999-09-27
YU62096A (sh) 1999-03-04
BG102438A (en) 1999-01-29
HUP9903734A2 (hu) 2000-03-28
CN1215993A (zh) 1999-05-05
HUP9903734A3 (en) 2000-04-28
AP9600883A0 (en) 1997-01-31
CA2232715A1 (en) 1997-05-29
SK63098A3 (en) 1999-05-07
NO982302D0 (no) 1998-05-20
GB9523752D0 (en) 1996-01-24
AR004335A1 (es) 1998-11-04
JPH10513481A (ja) 1998-12-22
CZ155498A3 (cs) 1999-03-17
NZ322053A (en) 1999-11-29
AU709560B2 (en) 1999-09-02
IS4706A (is) 1998-03-31

Similar Documents

Publication Publication Date Title
CO4480020A1 (es) Formulaciones farmaceuticas
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AR030541A1 (es) Acidos aminopropilfosfinicos, su utilizacion para la manufactura de medicamentos, y formulacion farmaceutica
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
CY1107675T1 (el) Φαρμακευτικα αλατα τραμαδολης
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
AR006678A1 (es) Derivados de macrolidas triciclicas, una composicion farmaceutica que los contiene, uso de los mismos para preparar medicamentos y procedimientopara su preparacion
PA8548701A1 (es) Azaindoles
CY1105648T1 (el) Filbanserin για την θεραπεια εξτραπυραμιδικων διαταραχων κινησης
SV1999000152A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
AR018862A1 (es) Formulacion farmaceutica de liberacion prolongada, mejorada para la administracion oral de nefazodona o una sal farmaceuticamente aceptable de la misma;forma de dosificacion oral que la comprende y uso de dicha formulacion para preparar dicha forma de dosificacion
BRPI0418026A (pt) derivados de fenilalanina ou sais farmaceuticamente aceitáveis destes, composição farmacêutica, antagonista de alfa4 integrina, e, agente terapêutico ou agente preventivo para doenças
CY1106137T1 (el) Φαρμακευτικη συνθεση πepιλαμβανουσα λουμιρακοξιμπη
CO5160287A1 (es) Formulacion de liberacion controlada de divalproex sodico
CO5640072A2 (es) Composiciones farmaceuticas que comprenden atorvastatina fabricada sin granulacion
ATE292453T1 (de) Antivirale arznei
AR011919A1 (es) FORMULACIoN EN COMPRIMIDOS O CÁPSULAS PARA TRAGAR DE PARACETAMOL (N-ACETIL-P-AMINOFENOL) Y PROCEDIMIENTO PARA PREPARARLA
AR013967A1 (es) UNA FORMULACION MEDICAMENTOSA PARA LA ADMINISTRACION ORAL DE PELLET DE DIFUSION CONTROLADA QUE TIENE LIBERACION CONTROLADA DE UN COMPUESTO ACTIVO QUE ES SELECCIONADO DEL ACIDO 1-CICLOPROPIL-7- [(S,S)-2,8-DIAZABICICLO [4.3.0] NON-8-IL ]-6-FLuOR-1,4-DIHIDRO-8-METOXI-4-OXO-3-QUINOLON CARBOXILICO O SALE
NO962752L (no) Anvendelse av 2,3-diaryl-1-benzopyranderivater ved fremstilling av et medikament for behandling og forebyggelse av benvevstap og osteoporose
UY27539A1 (es) Formulación farmacéutica
BR9809708A (pt) Composições farmacêuticas de peptìdeos tendo solubilidade baixa em meio fisiológico
PE20030830A1 (es) Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
JP2003055258A (ja) 安定化された組成物
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.